6
Hear’s a summary of the FDA approvals and trial data discussed in the provided text, presented in a numbered list:
- Datopotamab deruxtecan Approved for EGFR-Mutated NSCLC: The FDA approved datopotamab deruxtecan for patients with EGFR-mutated non-small cell lung cancer (NSCLC) who have progressed after prior treatments. [Link to article: https://www.ajmc.com/view/fda-approves-datopotamab-deruxtecan-for-egfr-mutated-nsclc]
- Telisotuzumab Vedotin Approved for c-Met Overexpressing NSCLC: The FDA approved telisotuzumab vedotin-tllv (Emrelis) for locally advanced or metastatic, non-squamous NSCLC with high c-Met protein overexpression, following prior systemic treatment. The phase 2 LUMINOSITY trial showed a 35% overall response rate and an average duration of response of 7.2 months.Common side effects included peripheral edema, fatigue, decreased appetite, and peripheral neuropathy. It’s also being studied in the TeliMET NSCLC-01 phase 3 trial. [Link to article: https://www.ajmc.com/view/teliso-v-approved-to-treat-advanced-nsclc-with-high-c-met-protein-overexpression]
- Adagrasib Plus Pembrolizumab Shows Prolonged PFS in KRAS-Mutated NSCLC: Updated data from the KRYSTAL-7 trial showed progression-free survival (PFS) exceeding 27 months for patients with newly diagnosed KRASG123-mutated NSCLC treated with adagrasib plus pembrolizumab as a first-line treatment.
